VINC (Vincerx Pharma) Tariff Resilience Score: 0/10 (As of Jul. 01, 2026)


What is Vincerx Pharma Tariff Resilience Score?

Vincerx Pharma has the Tariff Resilience Score of 0, which implies that the company might have .

Vincerx Pharma has Vincerx Pharma Inc has low tariff exposure due to its focus on R&D and domestic operations. The pharmaceutical industry often benefits from tariff exemptions, enhancing resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Vincerx Pharma might have .

Vincerx Pharma  (OTCPK:VINC) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Vincerx Pharma Tariff Resilience Score Related Terms

Vincerx Pharma Business Description

Address 1825 S. Grant Street, San Mateo, CA, USA, 94402
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.